Risk Reduction and Hemodynamics with Initial Combination Therapy in Pulmonary Arterial Hypertension.
Badagliacca R, D'Alto M, Ghio S, Argiento P, Bellomo V, Brunetti ND, Casu G, Confalonieri M, Corda M, Correale M, D'Agostino C, De Michele L, Galgano G, Greco A, Lombardi C, Manzi G, Mercurio V, Mulè M, Paciocco G, Papa S, Romeo E, Scelsi L, Stolfo D, Vitulo P, Naeije R, Vizza CD.
Badagliacca R, et al. Among authors: d agostino c.
Am J Respir Crit Care Med. 2021 Feb 15;203(4):484-492. doi: 10.1164/rccm.202004-1006OC.
Am J Respir Crit Care Med. 2021.
PMID: 32857597
Rationale: An initial oral combination of drugs is being recommended in pulmonary arterial hypertension (PAH), but the effects of this approach on risk reduction and pulmonary vascular resistance (PVR) are not known.Objectives: To test the hypothesis that a low-risk status would …
Rationale: An initial oral combination of drugs is being recommended in pulmonary arterial hypertension (PAH), but the effects of this appro …